• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial.

作者信息

Olkus Alexander, Dill Michael T

机构信息

Heidelberg Faculty of Medicine, Heidelberg University, Heidelberg, Germany.

Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxications, Heidelberg University Hospital, Heidelberg, Germany.

出版信息

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):676-679. doi: 10.21037/hbsn-2025-316. Epub 2025 Jul 25.

DOI:10.21037/hbsn-2025-316
PMID:40893741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393116/
Abstract
摘要

相似文献

1
Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial.胆管癌化疗之外：深入剖析TOPAZ-1试验的最新长期随访数据
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):676-679. doi: 10.21037/hbsn-2025-316. Epub 2025 Jul 25.
2
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.度伐利尤单抗或安慰剂联合吉西他滨和顺铂治疗晚期胆道癌（TOPAZ-1）：一项随机 3 期研究的更新总生存期数据。
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29.
3
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.度伐利尤单抗联合化疗治疗晚期胆管癌：III期TOPAZ-1研究的3年总生存更新数据
J Hepatol. 2025 May 15. doi: 10.1016/j.jhep.2025.05.003.
4
Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab.中性粒细胞与淋巴细胞比值（NLR）对接受吉西他滨、顺铂和度伐利尤单抗治疗的不可切除胆管癌患者的预后影响
World J Surg Oncol. 2025 Jul 1;23(1):258. doi: 10.1186/s12957-025-03834-x.
5
Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer.度伐利尤单抗联合化疗在多中心晚期胆管癌队列中的真实世界疗效及预后因素
Oncologist. 2025 Aug 4;30(8). doi: 10.1093/oncolo/oyae306.
6
Postoperative adjuvant chemotherapy and chemoimmunotherapy after radical resection for biliary tract cancer: a retrospective study.胆管癌根治性切除术后的术后辅助化疗和化疗免疫治疗：一项回顾性研究。
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf163.
7
Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.靶向程序性死亡蛋白1/程序性死亡蛋白配体1在胆管癌中的作用及现有数据
Immunotherapy. 2023 May;15(7):517-530. doi: 10.2217/imt-2022-0190. Epub 2023 Apr 3.
8
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.ABC-12：在度伐利尤单抗（MEDI4736）联合顺铂/吉西他滨用于晚期胆管癌患者的一线研究中探索微生物组。
Future Oncol. 2025 Jul 29:1-9. doi: 10.1080/14796694.2025.2539018.
9
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution.度伐利尤单抗联合顺铂和吉西他滨治疗晚期胆管癌的生存结果：来自意大利单一机构的真实世界结果
Oncology. 2025;103(8):677-698. doi: 10.1159/000541891. Epub 2024 Dec 6.
10
Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.女性生殖因素与胆道癌的关系：来自胆道癌汇集项目的研究。
J Hepatol. 2020 Oct;73(4):863-872. doi: 10.1016/j.jhep.2020.04.046. Epub 2020 May 11.

本文引用的文献

1
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.度伐利尤单抗联合化疗治疗晚期胆管癌：III期TOPAZ-1研究的3年总生存更新数据
J Hepatol. 2025 May 15. doi: 10.1016/j.jhep.2025.05.003.
2
Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.吉西他滨、顺铂和度伐利尤单抗免疫化疗治疗胆道癌患者的疗效、安全性和差异结局：一项多中心真实世界队列研究。
United European Gastroenterol J. 2024 Nov;12(9):1230-1242. doi: 10.1002/ueg2.12656. Epub 2024 Sep 20.
3
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
度伐利尤单抗或安慰剂联合吉西他滨和顺铂治疗晚期胆道癌（TOPAZ-1）：一项随机 3 期研究的更新总生存期数据。
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29.
4
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆管癌（TOPAZ-1）：一项随机、双盲、安慰剂对照3期试验的患者报告结局
Lancet Oncol. 2024 May;25(5):626-635. doi: 10.1016/S1470-2045(24)00082-2.
5
Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌患者：真实世界数据的探索性分析。
Target Oncol. 2024 Mar;19(2):213-221. doi: 10.1007/s11523-024-01044-1. Epub 2024 Feb 28.
6
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
7
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌：真实世界数据的早期探索性分析。
Liver Int. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641.
8
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
9
Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.根治性手术后胆道癌患者的强化随访计划和肿瘤学结局：一家三级医疗中心的 20 年经验。
Curr Oncol. 2022 Jul 19;29(7):5084-5090. doi: 10.3390/curroncol29070402.
10
Biliary tract cancer.胆道癌。
Lancet. 2021 Jan 30;397(10272):428-444. doi: 10.1016/S0140-6736(21)00153-7.